Sanofi Pasteur Inc.

Sanofi Pasteur Sa

Centers for Disease Control and Prevention

Connaught Laboratories Limited

Other

Center for Disease Control and Prevention

Acambis Inc.

Pasteur Merieux Serums & Vaccins

Ip2ipo Innovations Limited

Bruno Guy

Jean Lang

Véronique Barban

Richard M Kinney

Claire Y H Kinney

Robert S Becker

Robert C Huebner

Karen S Biscardi

Maryann B Gray

Lorne F Erdile

Jean Haensler

Remi Forrat

Marie-Jose B Quentin-Millet

Yves Girerd-Chambaz

Richard A Weltzin

Jeffrey Almond

Sebastian Johnston

Nicholas Glanville

Gary McLean

Rémi Forrat

Nicolas Burdin

Nathan Wylie Bartlett

Walton Ross

Sebastian Johnson

Nathan Bartlett

Claire Huang

The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.

Induction of cross-reactive cellular response against rhinovirus antigens

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.

Dengue serotype 1 attenuated strain

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Dengue serotype 2 attenuated strain

The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) ofor a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB ofor a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB ofor a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB ofor a lipidated fragment thereof is omitted; as well as vaccine compositions thereof. The LPS may, for example, be the LOS of a non-enteric Gram-negative bacterium such as

Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria

The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).

Method of immunization against the 4 dengue serotypes

The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising

The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising:

Method of immunization against the 4 serotypes of dengue fever

The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.

Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

Immunological combination compositions and methods

Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

This invention provides methods of inducing a protective or therapeutic immune response to Helicobacter infection in a mammal by parenterally administering to the mammal one or more Helicobacter antigens and an adjuvant selected from one or more of LT, CT, LTB, and CTB.

Growing community of inventors

Lyons, France

Bruno Guy